Centurium Capital, CITIC Capital and Hillhouse Capital are part of an investor group targeting a $4.6 billion take-private of China Biologic – just over a year after committing new equity to the US-listed company to protect it from other would-be acquirers.
Most healthcare-focused artificial intelligence start-ups in China focus on image-based diagnosis assistance, but deep learning-based drug discovery might be the key application
Malaysian sovereign wealth fund Khazanah Nasional has agreed to sell the Prince Court Medical Centre in Kuala Lumpur to local operator IHH Healthcare for about MYR1 billion ($244 million).
TPG Capital and Malaysian conglomerate Hong Leong Group have agreed to buy Columbia Pacific Management’s Southeast Asia hospital business for approximately $1.2 billion.
Qiming Venture Partners has led a $37 million Series B round for Insilico Medicine, a Hong Kong-based drug development company that uses artificial intelligence (AI).
Metro Pacific Hospitals Holdings (MPHH), a unit of Philippines-based conglomerate Metro Pacific Investments Corp. (MPIC), has filed for a domestic IPO. GIC is a minority shareholder in the business.
PAG has agreed to pay RMB3.8 billion ($532 million) for a 58% stake in a biotech unit of Zhejiang Hisun Pharmaceutical. It is being called the largest PE investment in China’s biotech space to date.
Quan Capital, a healthcare-focused venture capital firm established by the founder of US-listed Chinese drug developer Zai Lab, has closed its second fund with $275 million in commitments.
Qiming Venture Partners has led a $30million Series C round for Huimei Technology, a Chinese developer of artificial intelligence-enabled (AI) medical solutions provider.
Caisse de dépôt et placement du Québec (CDPQ) has agreed to join Brookfield Asset Management in its buyout of Australian hospital operator Healthscope, taking a significant minority stake for a consideration of more than A$300 million ($202 million).
HiFiBiO Therapeutics, a drug developer led by the former head of Asian cancer research at Sanofi, has completed a $67 million Series C funding round.
The Everstone Group has invested in Translumina Therapeutics, a global manufacturer of medical devices based in India.
Legend Capital has absorbed lessons from its corporate sponsor to build a diversified investment business across the US dollar and renminbi spaces. It is now trying to take LP relations to a new level
D&D Pharmatech, a South Korean biotechnology company, has raised a $137 million Series B round from a group of Korean and US investors.
Chinese contract research organization (CRO) Biocytogen has raised a RMB543 million ($78 million) Series D round led by China Life Insurance and SDIC Venture Capital, a VC arm of the State Development & Investment Corporation (SDIC).
Women remain underrepresented in start-up ecosystems across Asia, but for those who have taken the plunge, there is potential to make a social impact that transcends their respective target markets
SpeeDx, an Australian developer of molecular diagnostics solutions, has raised $15 million from US-based VC firm Northpond Ventures across two tranches.
Unison Capital has made the first investment from a newly created platform that will pursue a roll-up strategy in Japan’s hospital industry, with JPY50-60 billion ($467-560 million) set to be committed over the next five years.
Affirma Capital, a PE firm launched last year as a spin-out of Standard Chartered’s private equity business, has completed its first transaction as an independent firm with a $50 million investment in Indian supplements maker Tirupati Medicare.
TPG Capital and Fosun Pharma have agreed a $1.3 billion deal that will see Chinese hospital operator United Family Healthcare (UFH) absorbed by a special purpose acquisition company (SPAC) established by Antony Leung, formerly Greater China chairman at...
The doctors who own and operate Perth Radiologic Clinic know Allegro Funds from their time as a subsidiary of I-Med Networks. This familiarity helped the Australian GP secure one of its largest-ever deals
The Bill & Melinda Gates Foundation has made a rare direct investment in Southeast Asia, participating in an extended Series B round for Indonesian healthcare technology provider Halodoc.
Shenzhen Capital Group is looking to raise upwards of RMB2 billion ($290 million) for its first healthcare fund as the Chinese venture capital firm continues efforts to diversify its product offering.
Orum Therapeutics, a Korean biotechnology developer targeting cancer and rare diseases, has secured a $30 million Series B round from a group including IMM Investment and InterVest.